Thomson Reuters, a US-based provider of information for businesses and professionals, has partnered with Tigerlily Foundation, an education and advocacy organisation devoted to improving the quality of life for young women affected by breast cancer. Thomson Reuters is providing the Foundation with its NexCura cancer profiler tools, which allow patients and caregivers to enter information on a cancer diagnosis and receive detailed treatment information based on the latest peer-reviewed research.
Now available on the Tigerlily Foundation home page, www.tigerlilyfoundation.org, the cancer profiler tools provide a step-by-step approach to help users better understand diagnostic tests, treatment options and, in some cases, possible outcomes based on the experience of similar people treated within clinical trials. All of the information is based on a database of peer-reviewed clinical research. This individualised information helps patients have more informed discussions with their doctors, take charge of their health, and participate more fully in treatment decisions - with the aim of improving their medical prognoses.
Thomson Reuters' profiler tools provide customised information about treatment options for more than 30 chronic diseases including cancer, cardiovascular, pulmonary and urologic conditions. They have been used by more than 1 million people on websites of the American Heart Association, American Lung Association, Lance Armstrong Foundation, and academic and commercial healthcare organisations. According to the company, these tools use patented technology to lead users through an easy-to-follow questionnaire that matches the patient's diagnosis, diagnostic results, and disease stage with the relevant treatment options.
